E-viri
Recenzirano
Odprti dostop
-
Schrenk, Karin G.; Weschenfelder, Wolfram; Spiegel, Christian; Agaimy, Abbas; Stöhr, Robert; Hartmann, Arndt; Gaßler, Nikolaus; Drescher, Robert; Freesmeyer, Martin; Malouhi, Amer; Bürckenmeyer, Florian; Aschenbach, René; Teichgräber, Ulf; Kögler, Christine; Vogt, Matthias; Hofmann, Gunther O.; Hochhaus, Andreas
Journal of cancer research and clinical oncology, 08/2023, Letnik: 149, Številka: 9Journal Article
With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33 -fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET -fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.
